尼塞韦单抗对早产和足月婴儿呼吸道合胞病毒下呼吸道感染的疗效及对先天性心脏病和慢性肺病婴儿的药代动力学外推
该汇总分析纳入2b期和MELODY试验的2350名婴儿,评估尼塞韦单抗按体重给药方案。药代动力学数据支持将疗效外推至慢性肺病、先天性心脏病或极早产婴儿。
要点
- 尼塞韦单抗还降低RSV下呼吸道感染住院、极重度RSV、全因呼吸道住院和抗生素处方。
- 药代动力学数据支持将疗效外推至慢性肺病、先天性心脏病和极早产婴儿。
核心结论
- 单剂尼塞韦单抗可保护足月或早产健康婴儿免受医学就诊RSV下呼吸道感染、相关住院和重度RSV。
- 药代动力学数据支持将疗效外推至慢性肺病、先天性心脏病或极早产婴儿。
研究设计与样本
- 汇总2b期和MELODY随机对照试验,婴儿按2:1随机接受单次肌注尼塞韦单抗(体重<5 kg 50 mg,≥5 kg 100 mg)或安慰剂。
- 汇总分析纳入2350名婴儿(尼塞韦单抗组1564名,安慰剂组786名)。
- MEDLEY试验中婴儿按2:1随机接受尼塞韦单抗或帕利珠单抗,用于药代动力学外推分析。
关键数值与推荐
- 主要终点为给药后150天内医学就诊RSV下呼吸道感染发生率。
- 次要终点为医学就诊RSV下呼吸道感染住院数。
- 极重度RSV定义为因医学就诊RSV下呼吸道感染住院且需要补充氧气或静脉输液。
- 外推标准:MEDLEY中超过80%的婴儿需达到或超过预测有效目标血清暴露;总体MEDLEY人群94%达标,慢性肺病婴儿94%、先天性心脏病婴儿80%、极早产婴儿94%达标。
临床怎么用
- 对于足月或早产健康婴儿,单剂尼塞韦单抗可按体重给药(<5 kg 50 mg,≥5 kg 100 mg)预防RSV下呼吸道感染。
- 药代动力学数据支持在慢性肺病、先天性心脏病或极早产婴儿中使用尼塞韦单抗。
- 尼塞韦单抗可减少RSV相关住院、门诊就诊和抗生素使用。
局限性
- 外推至慢性肺病、先天性心脏病和极早产婴儿基于药代动力学数据而非直接疗效试验。
- 极重度RSV为探索性终点。
- 全因下呼吸道感染和呼吸道住院为预设探索性分析,门诊和抗生素使用为事后探索性分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In a phase 2b trial and the phase 3 MELODY trial, nirsevimab, an extended half-life, monoclonal antibody against respiratory syncytial virus (RSV), protected healthy infants born preterm or at full term against medically attended RSV lower respiratory tract infection (LRTI). In the MEDLEY phase 2-3 trial in infants at higher risk for severe RSV infection, nirsevimab showed a similar safety profile to that of palivizumab. The aim of the current analysis was to assess the efficacy of nirsevimab using a weight-banded dosing regimen in infants born between 29 weeks gestational age and full term. METHODS: Infants enrolled in the phase 2b and MELODY trials were randomised (2:1) to receive a single intramuscular injection of nirsevimab (infants weighing <5 kg received 50 mg; those weighing ≥5 kg received 100 mg) or placebo before the RSV season. Infants in MEDLEY were randomised (2:1) to receive one dose of nirsevimab (infants weighing <5 kg received 50 mg; those weighing ≥5 kg received 100 mg) followed by four monthly placebo doses, or five once-a-month intramuscular doses of palivizumab. We report a prespecified pooled efficacy analysis assessing the weight-banded dosing regimen proposed on the basis of the phase 2b and MELODY trials, in addition to extrapolated efficacy in infants with chronic lung disease, congenital heart disease, or extreme preterm birth (<29 weeks' gestational age) based on pharmacokinetic data from the phase 2-3 MEDLEY safety trial. For the pooled efficacy analysis, the primary endpoint was incidence of medically attended RSV LRTI through 150 days post-dose. The secondary efficacy endpoint was number of admissions to hospital for medically attended RSV LRTI. The incidence of very severe RSV LRTI was an exploratory endpoint, defined as cases of hospital admission for medically attended RSV LRTI that required supplemental oxygen or intravenous fluids. We also did a prespecified exploratory analysis of medically attended LRTI of any cause (in the investigator's judgement) and hospital admission for respiratory illness of any cause (defined as any upper respiratory tract infection or LRTI leading to hospital admission). Post hoc exploratory analyses of outpatient visits and antibiotic use were also done. Nirsevimab serum concentrations in MEDLEY were assessed using population pharmacokinetic methods and the pooled data from the phase 2b and MELODY trials. An exposure target was defined on the basis of an exposure-response analysis. To successfully demonstrate extrapolation, more than 80% of infants in MEDLEY had to achieve serum nirsevimab exposures at or above the predicted efficacious target. FINDINGS: Overall, 2350 infants (1564 in the nirsevimab group and 786 in the placebo group) in the phase 2b and MELODY trials were included in the pooled analysis. Nirsevimab showed efficacy versus placebo with respect to the primary endpoint of medically attended RSV LRTI (19 [1%] nirsevimab recipients vs 51 [6%] placebo recipients; relative risk reduction [RRR] 79·5% [95% CI 65·9-87·7]). Consistent efficacy was shown for additional endpoints of RSV LRTI hospital admission (nine [1%] nirsevimab recipients vs 21 [3%] placebo recipients; 77·3% [50·3-89·7]) and very severe RSV (five [<1%] vs 18 [2%]; 86·0% [62·5-94·8]). Nirsevimab recipients had fewer hospital admissions for any-cause respiratory illness (RRR 43·8% [18·8-61·1]), any-cause medically attended LRTI (35·4% [21·5-46·9]), LRTI outpatient visits (41·9% [25·7-54·6]), and antibiotic prescriptions (23·6% [3·8-39·3]). Among infants with chronic lung disease, congenital heart disease, or extreme preterm birth in MEDLEY, nirsevimab serum exposures were similar to those found in the pooled data; exposures were above the target in more than 80% of the overall MEDLEY trial population (94%), including infants with chronic lung disease (94%) or congenital heart disease (80%) and those born extremely preterm (94%). INTERPRETATION: A single dose of nirsevimab protected healthy infants born at term or preterm from medically attended RSV LRTI, associated hospital admission, and severe RSV. Pharmacokinetic data support efficacy extrapolation to infants with chronic lung disease, congenital heart disease, or extreme prematurity. Together, these data suggest that nirsevimab has the potential to change the landscape of infant RSV disease by reducing a major cause of infant morbidity and the consequent burden on caregivers, clinicians, and health-care providers. FUNDING: AstraZeneca and Sanofi.
引用
- Simões EAF, Madhi SA, Muller WJ, et al. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials. Lancet Child Adolesc Health. 2023. PMID: 36634694. doi:10.1016/S2352-4642(22)00321-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。